<DOC>
	<DOCNO>NCT00006359</DOCNO>
	<brief_summary>RATIONALE : Androgens cause growth prostate cancer cell . Drugs , leuprolide , goserelin , flutamide , bicalutamide , may stop adrenal gland make androgen . Radiation therapy use high-energy x-rays damage tumor cell . Giving drug together radiation therapy may kill tumor cell . PURPOSE : This phase II trial study well androgen suppression either leuprolide goserelin either flutamide bicalutamide together radiation therapy work treat patient prostate cancer .</brief_summary>
	<brief_title>Androgen Suppression Plus Radiation Therapy Treating Patients With Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine feasibility androgen-suppression therapy combine external-beam radiotherapy boost brachytherapy ( EBRT+BT ) patient intermediate-risk localized prostate cancer . - Determine safety EBRT+BT patient . - Determine , preliminary manner , efficacy EBRT+BT term rate local recurrence 5 year , time prostate-specific antigen failure , time first rectal/bladder injury , patient . OUTLINE : Patients receive either leuprolide intramuscularly goserelin subcutaneously every 12 week total 24 week . Patients also receive either oral flutamide three time daily oral bicalutamide daily 4 week . Within 4 week initiation androgen-suppression therapy , patient undergo external-beam radiotherapy ( EBRT ) daily , 5 day week , 5 week . At 2-4 week completion EBRT , patient undergo transrectal ultrasound-guided boost brachytherapy implant iodine I 125 palladium Pd 103 seed . Patients follow every 3 month 2 year every 6 month 4 year . PROJECTED ACCRUAL : A total 60 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Androgen Antagonists</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate Must one follow prognostic factor : Stage T12 , N0 ; prostatespecific antigen ( PSA ) ≤ 10 ng/mL ; Gleason score &gt; 6 Stage T12 , N0 ; PSA &gt; 10 ng/mL &lt; 20 ng/mL ; Gleason score ≤ 6 Stage T3a , N0 ; PSA ≤ 10 ng/mL ; Gleason score ≤ 6 Prostate volume &lt; 60 cc transrectal ultrasound No distant nodal metastases No metastatic disease bone scan , CT scan , MRI PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic : Bilirubin ≤ 1.5 time upper limit normal Renal : Not specify Other : Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No prior immunotherapy prostate cancer Chemotherapy : No prior chemotherapy prostate cancer Endocrine therapy : Prior androgensuppression therapy 4 week duration allow initiate within 4 week study radiotherapy No prior hormonal therapy Radiotherapy : No prior radiotherapy prostate cancer Surgery : No prior surgery prostate cancer No prior transurethral resection prostate Other : No prior alternative therapy ( e.g. , PCSPES ) prostate cancer</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage II prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
</DOC>